S100A9 and myeloproliferative disorder: Further validating the role of the S100A8/S100A9 axis, our experiments involving the genetic ablation of S100A9 in the hematopoietic compartment, but not in the stromal cells, revealed a significant improvement in the MPN phenotype and normalization of BM fibrosis.